BAC Collaborates with Sanofi Pasteur for Vaccine Purification

May 23, 2007
BioPharm International Editors

The Bio Affinity Company BAC BV (Naarden, the Netherlands, www.bac.nl) has entered into an agreement with Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccines arm of the Sanofi-Aventis Group, for the use of BAC's CaptureSelect customized affinity ligands for process-scale purification of some of its vaccine products.

The Bio Affinity Company BAC BV (Naarden, the Netherlands, www.bac.nl) has entered into an agreement with Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccines arm of the Sanofi-Aventis Group, for the use of BAC’s CaptureSelect customized affinity ligands for process-scale purification of some of its vaccine products. Manufactured using a proprietary yeast-based expression system, that is completely animal-free, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and are designed to provide enhanced stability and broad antigen-specific binding.
 

Related Content:

News